Bold claim: antimicrobial peptides (AMPs) hold the key to safer, more versatile oral health care, with the potential to outpace antibiotic resistance and support healing in ways traditional drugs can’t. But here’s where it gets controversial: translating lab power into everyday treatments is not straightforward. This overview preserves the core information while expanding explanations and examples to help newcomers grasp the topic.
Antimicrobial peptides in oral medicine: from mechanisms to clinical translation
KNOXVILLE, TN, December 12, 2025 — Antimicrobial peptides (AMPs) are small, naturally occurring polypeptides renowned for broad-spectrum antimicrobial activity, a reduced likelihood of driving resistance, and multifunctional roles, including immune modulation and promotion of tissue regeneration. This review synthesizes current knowledge on how AMPs are classified, how they kill microbes, and how they might be applied to major oral diseases such as dental caries, periodontitis, oral cancer, oral candidiasis, and oral mucositis. It also weighs the main hurdles to clinical use—stability, cytotoxicity, immunogenicity, and production costs—and outlines strategies to overcome them. Finally, it explores why AMPs could work in implant coatings, oral dressings, combination therapies, and as diagnostic markers, building a solid theoretical foundation for advancing oral disease treatment.
Oral diseases—caries, periodontitis, and oral cancer—affect roughly 3.5 billion people worldwide. Traditional approaches rely heavily on antibiotics, but rising bacterial resistance has eroded their effectiveness. This reality underscores the demand for safe, effective alternatives.
AMPs are a cornerstone of the innate immune system. These natural, small proteins largely act by directly disrupting microbial cell membranes, a mechanism that differs from many conventional antibiotics and helps minimize resistance development. Beyond their antimicrobial action, AMPs also regulate immune responses, dampen inflammation, and support tissue repair, all while exhibiting good compatibility with human cells.
A recent study published in Translational Dental Research (DOI: 10.1016/j.tdr.2025.100046) by a Chinese research group surveys AMP categories, their antimicrobial modes of action, and their roles in treating oral diseases. The authors illuminate several practical examples:
- Dental caries: Derivatives of Temporin-GHa, ZXR-2, and GH12 can inhibit cariogenic bacteria such as Streptococcus mutans, interfere with biofilm formation, and even assist in remineralizing teeth.
- Periodontitis: Human-derived AMPs (including α-defensins and β-defensins) and synthetic peptides (for instance, Nal-P-113) can kill periodontal pathogens, modulate inflammatory signaling by reducing pro-inflammatory cytokines, and enhance regeneration of periodontal tissues.
- Oral cancer: AMPs like Piscidin-1 and LL-37 can kill cancer cells through membrane disruption and apoptosis, while also shaping anti-tumor immune responses.
- Oral candidiasis: P-113 and Nisin A have shown notable efficacy against fungal infections, and peptides such as IB-367 and Histatin-5 aid healing in mucosal tissues affected by mucositis.
Several AMPs have advanced to clinical trials, including C16G2 for caries, Nal-P-113 for periodontitis, and P-113 for candidiasis, signaling real potential for clinical adoption. Beyond direct therapy, AMPs are being explored in implant coatings to prevent peri-implant infections, in oral dressings for sustained release, and in combination with antibiotics or nanoparticles to boost therapeutic outcomes. They also show promise as diagnostic markers for oral diseases by reflecting shifts in expression patterns.
Nevertheless, translating AMPs to clinical practice presents challenges. Oral enzymes, fluctuating pH, and high salt conditions can destabilize peptides. Cationic and amphiphilic properties, while central to antimicrobial function, may raise concerns about cytotoxicity and immunogenicity. Large-scale production remains expensive. To address these issues, researchers are pursuing several strategies: chemical modifications (such as N-acetylation and lipidation), nanocarrier delivery systems, sequence optimization with D-amino acids to improve stability, and heterologous expression in microbes or plants to reduce costs. As Feng notes, the multifunctionality of AMPs and their relatively low risk of inducing resistance position them as transformative tools in oral medicine.
Looking ahead, the authors advocate for deeper exploration of how AMPs interact with the oral microbiota and host cells, accelerated peptide screening through artificial intelligence, and the development of formulations tailored to the oral microenvironment to accelerate clinical use.
References
DOI: 10.1016/j.tdr.2025.100046
Original source: https://doi.org/10.1016/j.tdr.2025.100046
Funding: National Natural Science Foundation of China (82270980); Jinan Periodontitis Innovation Team (2021GXRC021); Shandong Province Major Innovation Project (2021SFGC0502); Shandong Province Oral Microbiome Innovation Team (2020KJK001).
About Translational Dental Research (TDR): TDR is the first specialized international journal dedicated to translational dental medicine, promoting research with clear clinical applications and fostering knowledge exchange among dental clinicians, scientists, and engineers across disciplines.
Chuanlink Innovations: A name that reflects the company’s mission to move ideas from concept to reality by connecting innovators and opportunities.
Related link: http://chuanlink-innovations.com
Would you like this rewritten piece to lean more toward a lay audience or stay firmly within a professional, scholarly tone? If you have a preferred length or focus (e.g., more on clinical applications, or a bigger emphasis on challenges), I can adjust accordingly.
